Blood Advances (Sep 2017)

Bone marrow sites differently imprint dormancy and chemoresistance to T-cell acute lymphoblastic leukemia

  • Xavier Cahu,
  • Julien Calvo,
  • Sandrine Poglio,
  • Nais Prade,
  • Benoit Colsch,
  • Marie-Laure Arcangeli,
  • Thierry Leblanc,
  • Arnaud Petit,
  • Frederic Baleydier,
  • Andre Baruchel,
  • Judith Landman-Parker,
  • Christophe Junot,
  • Jerome Larghero,
  • Paola Ballerini,
  • Eric Delabesse,
  • Benjamin Uzan,
  • Francoise Pflumio

Journal volume & issue
Vol. 1, no. 20
pp. 1760 – 1772

Abstract

Read online

Abstract: T-cell acute lymphoblastic leukemia (T-ALL) expands in various bone marrow (BM) sites of the body. We investigated whether different BM sites could differently modulate T-ALL propagation using in vivo animal models. We observed that mouse and human T-ALL develop slowly in the BM of tail vertebrae compared with the BM from thorax vertebrae. T-ALL recovered from tail BM displays lower cell-surface marker expression and decreased metabolism and cell-cycle progression, demonstrating a dormancy phenotype. Functionally, tail-derived T-ALL exhibit a deficient short-term ex vivo growth and a delayed in vivo propagation. These features are noncell-autonomous because T-ALL from tail and thorax shares identical genomic abnormalities and functional disparities disappear in vivo and in prolonged in vitro assays. Importantly tail-derived T-ALL displays higher intrinsic resistance to cell-cycle–related drugs (ie, vincristine sulfate and cytarabine). Of note, T-ALL recovered from gonadal adipose tissues or from cocultures with adipocytes shares metabolic, cell-cycle, and phenotypic or chemoresistance features, with tail-derived T-ALL suggesting adipocytes may participate in the tail BM imprints on T-ALL. Altogether these results demonstrate that BM sites differentially orchestrate T-ALL propagation stamping specific features to leukemic cells such as quiescence and decreased response to cell-cycle–dependent chemotherapy.